HU222243B1 - Eljárás hányás kezelésére alkalmas piperidin- vagy azabiciklooktán származékokat tartalmazó gyógyászati készítmények előállítására - Google Patents

Eljárás hányás kezelésére alkalmas piperidin- vagy azabiciklooktán származékokat tartalmazó gyógyászati készítmények előállítására Download PDF

Info

Publication number
HU222243B1
HU222243B1 HU9401676A HU9401676A HU222243B1 HU 222243 B1 HU222243 B1 HU 222243B1 HU 9401676 A HU9401676 A HU 9401676A HU 9401676 A HU9401676 A HU 9401676A HU 222243 B1 HU222243 B1 HU 222243B1
Authority
HU
Hungary
Prior art keywords
vomiting
pharmaceutically acceptable
treatment
preparation
diphenylmethyl
Prior art date
Application number
HU9401676A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9401676D0 (en
HUT71550A (en
Inventor
Manoj C. Desai
John A. Lowe Iii.
John W. Watson
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HU9401676D0 publication Critical patent/HU9401676D0/hu
Publication of HUT71550A publication Critical patent/HUT71550A/hu
Publication of HU222243B1 publication Critical patent/HU222243B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
HU9401676A 1993-06-04 1994-06-03 Eljárás hányás kezelésére alkalmas piperidin- vagy azabiciklooktán származékokat tartalmazó gyógyászati készítmények előállítására HU222243B1 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/072,629 US5393762A (en) 1993-06-04 1993-06-04 Pharmaceutical agents for treatment of emesis

Publications (3)

Publication Number Publication Date
HU9401676D0 HU9401676D0 (en) 1994-09-28
HUT71550A HUT71550A (en) 1995-12-28
HU222243B1 true HU222243B1 (hu) 2003-05-28

Family

ID=22108825

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9401676A HU222243B1 (hu) 1993-06-04 1994-06-03 Eljárás hányás kezelésére alkalmas piperidin- vagy azabiciklooktán származékokat tartalmazó gyógyászati készítmények előállítására

Country Status (19)

Country Link
US (1) US5393762A (cg-RX-API-DMAC10.html)
EP (1) EP0627221B1 (cg-RX-API-DMAC10.html)
JP (1) JP2671972B2 (cg-RX-API-DMAC10.html)
KR (1) KR100190729B1 (cg-RX-API-DMAC10.html)
CN (1) CN1100535C (cg-RX-API-DMAC10.html)
AT (1) ATE209490T1 (cg-RX-API-DMAC10.html)
AU (1) AU666077B2 (cg-RX-API-DMAC10.html)
CA (1) CA2124990C (cg-RX-API-DMAC10.html)
DE (1) DE69429208T2 (cg-RX-API-DMAC10.html)
DK (1) DK0627221T3 (cg-RX-API-DMAC10.html)
ES (1) ES2164088T3 (cg-RX-API-DMAC10.html)
HU (1) HU222243B1 (cg-RX-API-DMAC10.html)
IL (1) IL109802A (cg-RX-API-DMAC10.html)
MY (1) MY115310A (cg-RX-API-DMAC10.html)
NZ (1) NZ260674A (cg-RX-API-DMAC10.html)
PT (1) PT627221E (cg-RX-API-DMAC10.html)
RU (1) RU2135179C1 (cg-RX-API-DMAC10.html)
TW (1) TW318791B (cg-RX-API-DMAC10.html)
ZA (1) ZA943896B (cg-RX-API-DMAC10.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9206073A (pt) * 1991-05-31 1994-12-06 Pfizer Derivados de quinuclidina
SK282203B6 (sk) * 1991-06-20 2001-12-03 Pfizer Inc. Fluoroalkoxybenzylamínové deriváty heterocyklov obsahujúcich dusík, spôsob ich prípravy, medziprodukty, spôsob prípravy medziproduktov, použitie a farmaceutický prostriedok
ES2149767T5 (es) 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
EP0687268B1 (en) * 1993-03-04 1998-05-27 Pfizer Inc. Spiroazacyclic derivatives as substance p antagonists
GB9305718D0 (en) 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
DE69617226T2 (de) * 1995-03-27 2002-07-25 Hisamitsu Pharmaceutical Co., Inc. Piperidinderivate.
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW458774B (en) * 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
US6329396B1 (en) 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
GB9708484D0 (en) 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
AU736542B2 (en) * 1997-06-27 2001-08-02 Merck Sharp & Dohme Limited Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
EP1145714A4 (en) * 1998-11-27 2004-12-15 Takeda Chemical Industries Ltd DRUGS
IL133077A0 (en) * 1999-01-29 2001-03-19 Pfizer Prod Inc Azithromycin combination for emesis control in dogs
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
RU2197961C2 (ru) * 2000-07-17 2003-02-10 Центр по разработке эластомеров Казанского государственного технологического университета Средство для профилактики и купирования тошноты и рвоты
RU2183118C1 (ru) * 2001-07-12 2002-06-10 Государственный научный центр РФ Институт медико-биологических проблем РАН Способ профилактики вестибуловегетативных расстройств у человека в условиях воздействий, вызывающих укачивание
EP1411946A1 (en) * 2001-07-20 2004-04-28 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
BRPI0507325A (pt) * 2004-01-30 2007-07-03 Pfizer Prod Inc antagonistas dos receptores nk-1 para melhorar a recuperação da anestesia
HUE034099T2 (en) * 2004-01-30 2018-01-29 Zoetis Services Llc Antimicrobial preservatives for the delivery of multidose formulations using beta-cyclodextrins for liquid dosage forms
DK1713801T3 (da) * 2004-02-02 2008-03-17 Pfizer Prod Inc Fremgangsmåde til fremstilling af 1-(2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amin
WO2014197137A1 (en) * 2013-04-29 2014-12-11 Howard Brooks-Korn Diversion-resistant formulation
WO2018175670A1 (en) 2017-03-22 2018-09-27 The Research Foundation For The State University Of New York Matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8527052D0 (en) * 1985-11-02 1985-12-04 Beecham Group Plc Compounds
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
JPH072740B2 (ja) * 1990-06-01 1995-01-18 フアイザー・インコーポレイテツド 3―アミノ―2―アリールキヌクリジン
DE69106365T2 (de) * 1990-07-23 1995-05-04 Pfizer Chinuclidinderivate.
ATE121389T1 (de) * 1990-09-28 1995-05-15 Pfizer Ringverknüpfte analoge von stickstoffenthaltenden nichtaromatischen heterocyclen.
CA2100163A1 (en) * 1991-01-10 1992-07-11 John A. Lowe, Iii N-alkyl quinuclidinium salts
DE69200921T2 (de) * 1991-03-01 1995-05-04 Pfizer 1-azabicyclo[3.2.2]nonan-3-aminderivate.
AU647592B2 (en) * 1991-03-26 1994-03-24 Pfizer Inc. Stereoselective preparation of substituted piperidines
RU2092486C1 (ru) * 1991-05-22 1997-10-10 Пфайзер Инк. Замещенные 3-аминохинуклидины
BR9206073A (pt) * 1991-05-31 1994-12-06 Pfizer Derivados de quinuclidina
SK282203B6 (sk) * 1991-06-20 2001-12-03 Pfizer Inc. Fluoroalkoxybenzylamínové deriváty heterocyklov obsahujúcich dusík, spôsob ich prípravy, medziprodukty, spôsob prípravy medziproduktov, použitie a farmaceutický prostriedok
TW202432B (cg-RX-API-DMAC10.html) * 1991-06-21 1993-03-21 Pfizer
ES2149767T5 (es) * 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
EP0607164B1 (en) * 1991-09-26 2002-05-02 Pfizer Inc. Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists
ES2111650T3 (es) * 1991-11-12 1998-03-16 Pfizer Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
JP2656702B2 (ja) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
DE69331190T2 (de) * 1992-05-18 2002-04-18 Pfizer Inc., New York Überbrückte azabicyclische derivate als substanz p antagonisten
ES2147759T3 (es) * 1992-12-10 2000-10-01 Pfizer Heterociclos no aromaticos sustituidos con aminometileno y uso como antagonistas de la sustancia p.
EP0687268B1 (en) * 1993-03-04 1998-05-27 Pfizer Inc. Spiroazacyclic derivatives as substance p antagonists
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
AU5776099A (en) * 1998-08-14 2000-03-06 Via, Inc. Mobile robotic snake

Also Published As

Publication number Publication date
US5393762A (en) 1995-02-28
DK0627221T3 (da) 2002-02-11
IL109802A (en) 2002-04-21
CA2124990C (en) 1999-04-20
KR950000144A (ko) 1995-01-03
DE69429208T2 (de) 2002-05-23
JPH0753362A (ja) 1995-02-28
PT627221E (pt) 2002-04-29
TW318791B (cg-RX-API-DMAC10.html) 1997-11-01
AU6452194A (en) 1994-12-15
ZA943896B (en) 1995-12-04
RU94020410A (ru) 1996-05-10
HU9401676D0 (en) 1994-09-28
CN1121806A (zh) 1996-05-08
JP2671972B2 (ja) 1997-11-05
NZ260674A (en) 2000-07-28
AU666077B2 (en) 1996-01-25
HUT71550A (en) 1995-12-28
ES2164088T3 (es) 2002-02-16
IL109802A0 (en) 1994-08-26
KR100190729B1 (ko) 1999-06-01
EP0627221A3 (en) 1995-08-02
RU2135179C1 (ru) 1999-08-27
EP0627221B1 (en) 2001-11-28
DE69429208D1 (de) 2002-01-10
EP0627221A2 (en) 1994-12-07
CN1100535C (zh) 2003-02-05
ATE209490T1 (de) 2001-12-15
MY115310A (en) 2003-05-31

Similar Documents

Publication Publication Date Title
EP0627221B1 (en) Substance P antagonists for the treatment of emesis
KR100197452B1 (ko) 구토 치료를 위한 nk-1 수용체 길항제 및 5ht3 수용체 길항제
EP0799037B1 (en) Compositions for treating allergic rhinitis and other disorders comprising descarboethoxyloratadine
EP0533280B2 (en) Novel medical use for tachykinin antagonists
US20010006972A1 (en) Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
US6329394B1 (en) Medical use for tachykinin antagonists
EP0216555B1 (en) Use of dioxopiperidine derivatives in the treatment of anxiety, for the reduction of chronic abnormally high brain levels of serotonin or 5-hydroxy-indoleacetic acid, and in the treatment of bacterial or viral infections
CZ290115B6 (cs) Farmaceutický prostředek
EP0873753A1 (en) Use of NK-1 receptor antagonists for the manufacture of a medicament in the treatment of symptoms of irritable bowel syndrome
CA2167004C (en) Agent for treating mental disorders associated with cerebrovascular disorders
US5340826A (en) Pharmaceutical agents for treatment of urinary incontinence
US20040006135A1 (en) Combination treatment for depression and anxiety
CA2357901A1 (en) Combination treatment for depression and anxiety
US5750535A (en) Pharmaceutical agents for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
EA000531B1 (ru) Активное вещество при производстве фармацевтического препарата для лечения травматического повреждения головного мозга
AU751590B2 (en) Acetylcholine enhancers
EP0721778A2 (en) NK-1 receptor antagonists for the treatment of neuronal injury and stroke
JP2001139490A (ja) うつ病及び不安に対する組合せ治療
US4904673A (en) Agent for treating bradycardia and bradyarrhythmia
Meyer et al. The novel dihydronaphthyridine Ca2+ channel blocker CI-951 improves CBF, brain pHi, and EEG recovery in focal cerebral ischemia
JP2955550B2 (ja) 後発性嘔吐の治療のためのnk−1レセプタ−アンタゴニスト
US5026699A (en) Use of 5,11-dihydro-6H-pyrido[2,3-b][1,4]-benzodiazepin-6-ones substituted in the 11-position for treating bradycardia and bradyarrhythmia in human and veterinary medicine
AU7177100A (en) NK-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
IE913211A1 (en) Use of n-(1-hexahydroazepinylalkyl) acetamides in the¹preparation of medicaments for the treatment of cholinergic¹transmission disorders
HK1054873A1 (en) Pharmaceutical composition based on cocaethylene and use thereof for treating psychoactive substance dependence

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20030325

MM4A Lapse of definitive patent protection due to non-payment of fees